Ghana's Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000
The Aster Guardians Global Nursing Award was launched in 2021 to recognize the invaluable role of nurses in healthcare. The award was presented by His Excellency Sheikh Nahyan bin Mabarak Al Nahyan, Minister of Tolerance and Coexistence, UAE in presence of Dr Azad Moopen and Alisha Moopen. During this year's ceremony, Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, shared a special message applauding Aster's effort in putting a spotlight on the contributions of nurses worldwide.
Nurse Naomi Ohene Oti said, 'For over two decades, I've witnessed the inequities in cancer care firsthand and dedicated myself to closing these gaps through training, outreach, and system-level change. This award will help amplify our impact – scaling training, building faculty, and inspiring the next generation of oncology nurses across Africa.'
Dr. Azad Moopen, Founder Chaiman, Aster DM Healthcare stated, 'Nurse Naomi Ohene Oti has redefined what it means to be a nurse – not just as a caregiver but as an innovator, leader, and changemaker. Her contributions uplift not only patients but the entire healthcare ecosystem, setting a gold standard for others to follow.
Alisha Moopen, Managing Director and Group CEO, Aster DM Healthcare added, 'Naomi Ohene Oti's story is a powerful reminder of the quiet heroism that unfolds every day in hospitals, clinics, and communities across the world. We are incredibly proud to shine a global spotlight on her work, and through her, honour the millions of nurses who keep healthcare systems running and humanity thriving.'
About Aster DM Healthcare:
Founded in 1987 by Dr. Azad Moopen, Aster DM Healthcare is a leading integrated healthcare provider, with a strong presence across seven countries. Aster is committed to the vision of providing accessible and high-quality healthcare, from primary to quaternary services, with its promise of 'We will treat you well'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Marion County Public Schools Selects PowerSchool Attendance Intervention to Reduce Chronic Absenteeism and Strengthen Family Engagement
FOLSOM, Calif.--(BUSINESS WIRE)-- PowerSchool, a leading provider of cloud-based software for K-12 education, today announced that Marion County Public Schools (MCPS), in Ocala, Florida, has selected PowerSchool Attendance Intervention to help reduce chronic absenteeism, increase overall student attendance, and improve communication with families across its more than 60 schools. Funded through a federal Stronger Connections grant, MCPS is the first district in Florida to implement the solution, which will launch in time for the 2025-2026 school year. The district aims to reduce its chronic absenteeism rate by 12% (32% to 20%) and to ultimately reach 95% average daily attendance across all student populations. Achieving this goal would place MCPS as a leader in tackling chronic absenteeism amongst districts in Florida, where the average daily attendance was 91.4% as of the latest data available, from the 2023-24 school year. Chronic absenteeism (students missing 10% or more of the school year) also increased significantly in Florida schools since the pandemic, rising more than 50% from the 2018-19 school year to the 2023-24 school year. 'We've made incremental progress year over year, but we need a bigger shift,' said Yvette del Nodal, Director, Mental Health & Wellness, Marion County Public Schools. 'PowerSchool Attendance Intervention stood out because it's not just about boosting attendance—it's about reaching families, in their home language, and building relationships that support students in the long term.' Attendance Intervention is a research-backed solution that helps schools and districts detect early signs of absenteeism and implement targeted interventions. The solution combines early warning analytics, customizable workflows, and automated communication tools to support students' most at risk. A Johns Hopkins University School of Education study found that districts using Attendance Intervention saw measurable improvements in attendance, including a reduction in chronic absenteeism and increased engagement between families and school staff. MCPS includes 33 elementary schools, nine middle schools, seven high schools, and a range of charter, virtual, and technical learning facilities. In addition to addressing communication, MCPS will use Attendance Intervention to deliver positive reinforcement strategies, such as classroom celebrations and attendance-based incentives. The district also launched a Community Attendance Council to address out-of-school barriers like transportation, health, and housing instability. Marion County Public Schools serves more than 45,000 students across Central Florida, many of whom speak languages other than English like Spanish, Gujarati, Vietnamese, Haitian-Creole, Mandarin, Portuguese, and Zhongwen (Hanyu). Attendance Intervention's automatic translation feature allows staff to send and receive messages in families' home languages directly to their mobile phones without requiring app downloads or login credentials. About PowerSchool PowerSchool is a leading provider of cloud-based software for K-12 education in North America. Its mission is to empower educators, administrators, and families to ensure personalized education for every student journey. PowerSchool offers end-to-end product clouds that connect the central office to the classroom to the home with award-winning products including Schoology Learning and Naviance CCLR, so school districts can securely manage student data, enrollment, attendance, grades, instruction, assessments, human resources, talent, professional development, special education, data analytics and insights, communications, and college and career readiness. PowerSchool supports over 60 million students in more than 90 countries and over 18,000 customers, including more than 90 of the top 100 districts by student enrollment in the United States. © PowerSchool. PowerSchool and other PowerSchool marks are trademarks of PowerSchool Holdings, Inc. or its subsidiaries. ** Other names and brands may be claimed as the property of others.
Business Wire
an hour ago
- Business Wire
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. 'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.' About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Business Wire
an hour ago
- Business Wire
ieso Sharpens Focus on AI-Powered Mental Healthcare with Sale of UK Telecare Services Business
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- ieso, a global leader in evidence-based digital mental health, today announced the sale of its UK telecare services business to Mindler, a leading pan-European digital therapy provider. The acquisition is specific to ieso's NHS-facing care operations in the UK, including delivery of typed and video therapy services. Mindler's press release is available here. "As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we." - Kent Tangen, CEO, ieso Share The parent company, ieso Digital Health Limited, remains fully independent and continues to operate under the ieso brand. With the sale now complete, ieso is entirely focused on scaling its clinical-grade generative AI platform, Velora, to deliver safe, effective, personalized mental health support via SaaS integration into clinical workflows. 'We're proud to have supported thousands of lives through ieso's UK telecare services. That legacy will always be a part of who we are,' said Kent Tangen, CEO at ieso. 'With those operations now in excellent hands at Mindler, ieso is committed to building the future we've long envisioned: delivering safe, effective AI-powered mental healthcare at scale. Our immediate focus is in the US, but our mission is global. As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we.' ieso was advised on the transaction by Cooley LLP and Artis Finance. About ieso ieso is a pioneer in AI-powered mental healthcare, combining clinical expertise with advanced technology to help more people feel better, faster. Its latest product, Velora, is a next-generation generative AI-based program that delivers outcomes on par with human-delivered care and is designed to integrate seamlessly into existing clinical workflows. Backed by over a decade of research and real-world data, ieso is focused on increasing access to safe, effective, and scalable mental health support in the US and beyond. To learn more or request a demo, visit
